Despite new data, the FDA extended the review period for the use of Tarceva in lung cancer until April 2010, following the submission of new data by OSI.

We don't really know what they thought about the data, but the delay could mean they are looking for more robust followup before rendering a decision.

http://www.pipelinereview.com/index.php/2010011532088/Small-Molecules/FD...

Lung cancer is the foremost cause of cancer-related deaths in the United States and Europe. The most common type of lung cancer NSCLC occurs from the tissues of the lung. Current treatments are being carried to destroy tumor cells or prevent further tumor growth. Approaches to treatment include surgery chemotherapy biological therapies like monoclonal antibodies and radiation. Avastin and Tarceva are two agents which are targeted against specific proteins that are often found in cancer cells. The proteins are involved in the growth and spread of the cancer cells.